
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tessellis spa | BIT:TSL | Italy | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2025 | 0.202 | 0.203 | 0.21 | 0.201 | 0.201 | 3,588,390 | 16:37:07 |
RNS Number:5893T Tissue Science Laboratories PLC 23 December 2003 23 December 2003 TSL appoints new Technical Director Aldershot, UK - Tissue Science Laboratories plc (LSE: TSL), the medical devices company, announces the appointment of Stephen Bloor as Technical Director to the Board of Directors effective from 17 December 2003. Stephen Bloor, aged 39, joined the Company in April 2000 as New Product Development (NPD) Manager and was promoted to Associate Director of NPD in the latter half of 2002. He was previously with Johnson & Johnson as Project Manager of the wound care product development group, and, prior to that, he was Section Head of Biochemistry at Biocure Limited. In his new role as Technical Director, Stephen will be responsible for new product development, clinical research and regulatory affairs and will have Board level responsibility for all technical matters relating to TSL's current and future products. He has been performing this function since September and his election represents the Board's confidence in his ability. The Company confirms that no other details are required to be disclosed under Rule 15 and Paragraph F of Schedule 2 of the AIM Rules with respect to Mr Bloor. -Ends- Enquiries: TSL plc Tel: 01252 333 002 Martin Hunt, Chief Executive David Jennings, Finance Director Hogarth PR Tel: 020 7357 9477 Melanie Toyne-Sewell Notes to Editors Background on TSL Founded in 1995 with headquarters in Aldershot, Hampshire, TSL is a medical technology company specialising in tissue repair and replacement with a proprietary sheet product derived from porcine dermis. TSL has launched successfully two different formulations of the product and built a development pipeline that addresses the large and fast growing surgical implant and woundcare markets. The Company floated in November 2001 and is listed on the Alternative Investment Market. TSL has a family of products based on the same core technology. Each product has been adapted, with unique properties, to make it suitable for use in different applications. PelvicolTM/Permacol Surgical Implant (SI) is sold by Bard in the US and Europe for urology and gynaecology applications; Permacol SI (general surgery) is sold for complex hernia repair in the US and Europe; Permacol SI (ENT, plastic and reconstruction) is sold in Europe for head and face applications; Permacol Injection (UBA) is an injectable form of Permacol used as a urethral bulking agent to treat female stress incontinence. The Company has also recently signed a worldwide distribution agreement with Zimmer for the application of Permacol (SI) in the orthopaedic market. Further variations of the sheet and injectable forms of Permacol are being developed. Bard is a trademark of C.R. Bard, Inc. or an affiliate. This information is provided by RNS The company news service from the London Stock Exchange END BOANKNKBCBDKQBB
1 Year Tessellis Chart |
1 Month Tessellis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions